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Two articles in this issue of the Journal provide fresh insights into the management of malignant pleural mesothelioma (MPM), a very challenging disease. The article 
by Bovolato et al.1 retrospectively analyzes outcomes in 1365 MPM patients treated at 
six Italian institutions over a 30-year period, identifies significant prognostic factors, and 
attempts to define the contribution of surgical resection to overall survival. The article by 
Cho et al.2 at the University of Toronto reports the results of a novel phase II trial of imme-
diate preoperative hemithoracic intensity-modulated radiation therapy (IMRT) followed by 
extrapleural pneumonectomy (EPP). In highly selected patients, this approach was associ-
ated with the best 3-year overall survival (84%) reported to date in MPM.
The Italian study corroborates data recently published by the International Association 
for the Study of Lung Cancer (IASLC) International Staging and Prognostic Factors 
Committee,3 including the substantial gap between clinical and pathological staging, the 
significance of prognostic factors such as tumor histology and patient age, and the appar-
ently better outcomes associated with combined modality therapy. Important aspects of this 
analysis are the large number of patients analyzed, the long follow-up, and the apparently 
uniform approaches to surgical resection. Significant limitations include the variability in 
adjuvant therapy and the long duration of the study. Both radiation and chemotherapy for 
MPM have evolved considerably during the past 30 years, but little information about the 
criteria for adjuvant therapy or the treatment details is provided.
As in the analysis of the IASLC MPM database, it is difficult to identify differences 
in outcome based on surgical approach, that is, EPP versus pleurectomy/decortication. 
 Stage-specific analyses are based on numbers of patients too small to be meaningful, and 
there are likely inherent differences between these two groups because surgeons apparently 
chose to perform an EPP predominantly in patients with more locally advanced disease. 
Even the analysis of outcome for multi- versus single-modality therapy may be strongly 
influenced by biases in patient selection. Perhaps the most convincing aspect of these 
results is that they are completely congruent with those of other large series, including the 
IASLC MPM database.
The prospective trial from the Toronto group proposes a completely new treatment 
algorithm. Immediate preoperative hypofractionated radiation has been used in other 
malignancies such as rectal cancer. Using it before EPP required close interaction with an 
experienced surgeon who can reliably select patients for this operation because not pro-
ceeding to pneumonectomy would expose the patient to severe radiation pneumonitis. This 
new treatment strategy does not seem to yield better local control than the more conven-
tional approach of postoperative hemithoracic radiation after EPP4 but is associated with 
remarkably good survival in highly selected patients. Careful patient selection based on 
tumor stage, known prognostic factors, and cardiopulmonary reserve is clearly pivotal in 
this approach. The authors propose the intriguing hypothesis that preoperative IMRT may 
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activate the immune system against tumor. Correlative studies 
to support or refute this idea are needed. As the authors point 
out, preoperative IMRT and EPP are applicable to a minority 
of patients (18% in their experience), but their results are suf-
ficiently promising to warrant larger, preferably multicenter 
trials to test this treatment strategy. Such trials will also need 
to formalize the guidelines for adjuvant chemotherapy that, 
in the Toronto study, was administered in a very liberal time 
frame (<26 weeks postoperatively).
What both of these studies emphasize is the need to 
optimize patient selection in future trials. Historically, MPM 
studies have lumped together very heterogeneous patient pop-
ulations, an approach that would not be acceptable in other 
malignancies. Clearly, conventional surgery, chemotherapy, 
and radiation have all had a modest effect on MPM, and novel 
treatment strategies are needed. With multiple reports now 
confirming the importance of both specific prognostic factors 
and tumor stage, future trials of either conventional or novel 
treatment modalities must have more stringent inclusion crite-
ria. Outcomes in MPM patients are much more variable than 
originally thought. To make progress in this difficult cancer, 
strictly defined treatment5 needs to be studied prospectively in 
strictly defined MPM patient cohorts.
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